<?xml version="1.0" encoding="UTF-8"?>
<ref id="R3">
 <label>3</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Granier</surname>
    <given-names>C</given-names>
   </name>, 
   <name name-style="western">
    <surname>De Guillebon</surname>
    <given-names>E</given-names>
   </name>, 
   <name name-style="western">
    <surname>Blanc</surname>
    <given-names>C</given-names>
   </name>, 
   <etal>et al</etal>
  </person-group>
  <article-title>Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer</article-title>. 
  <source>ESMO Open</source>
  <year>2017</year>;
  <volume>2</volume>:
  <elocation-id>e000213</elocation-id>. 
  <pub-id pub-id-type="doi">10.1136/esmoopen-2017-000213</pub-id>
  <?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/28761757?>
  <pub-id pub-id-type="pmid">28761757</pub-id>
 </mixed-citation>
</ref>
